Maternal and perinatal factors related to maternal-infant transmission of HIV-1 in the P2C2 HIV study: the role of EBV shedding. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV-1 Infection (P2C2 HIV) Study Group

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 15;19(5):462-70. doi: 10.1097/00042560-199812150-00004.

Abstract

The association of maternal and perinatal factors with mother-infant transmission of HIV-1 was examined in a prospective multicenter cohort of singleton live births to 508 HIV-1-infected women with children of known HIV-1 infection status (91 [18%] HIV-1-infected, 417 [82%] uninfected). From multivariate logistic regression, independent predictors of HIV-1 transmission included maternal CD4 percentage (CD4%) (odds ratio [OR] per 10% increase in CD4% = 0.70; p = .003), ruptured membranes <24 hours (OR = 3.15; p = .02), and maternal bleeding (OR = 2.90; p = .03), whereas maternal zidovudine (ZDV) use was marginally associated (OR = 0.60; p = .08). The associations of maternal urinary cytomegalovirus (CMV) shedding, oropharyngeal Epstein-Barr virus (EBV) shedding, and serology profiles during pregnancy with HIV-1 transmission were examined in the subset of mothers in whom the CMV and EBV measurements were available. Maternal EBV seropositivity, CMV shedding, and CMV seropositivity were 100% (279 of 279), 7% (16 of 229), and 92% (270 of 274), respectively. These rates did not differ between transmitting and nontransmitting mothers. In univariate analyses, maternal EBV shedding was higher among transmitting than nontransmitting mothers (40 of 49 [82%] compared with 154 of 226 [68%]; p = .06) and was independently associated with transmission in multivariate logistic analyses adjusting for CD4%, ruptured membranes, and ZDV use, with an OR of 2.45 (95% confidence interval (CI), 1.03-5.84; p = .04). This permits the conclusion that EBV shedding is associated with maternal-infant HIV-1 transmission, independent of CD4%.

Publication types

  • Multicenter Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-HIV Agents / therapeutic use
  • CD4 Lymphocyte Count
  • CD4-CD8 Ratio
  • Cohort Studies
  • Cytomegalovirus / isolation & purification
  • Cytomegalovirus / physiology
  • Female
  • Gestational Age
  • HIV Infections / complications
  • HIV Infections / transmission*
  • HIV Infections / virology
  • HIV-1*
  • Herpesviridae Infections / complications
  • Herpesviridae Infections / virology
  • Herpesvirus 4, Human / isolation & purification
  • Herpesvirus 4, Human / physiology*
  • Humans
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical*
  • Male
  • Oropharynx / virology
  • Pregnancy
  • Pregnancy Complications, Infectious* / virology
  • Prospective Studies
  • Risk Factors
  • Urine / virology
  • Uterine Hemorrhage / complications
  • Virus Shedding*
  • Zidovudine / therapeutic use

Substances

  • Anti-HIV Agents
  • Zidovudine